Akero Therapeutics Inc

NASDAQ:AKRO   3:59:57 PM EDT
26.37
+0.13 (+0.50%)
Products, Regulatory

Akero Therapeutics Receives European Medicines Agency Priority Medicines (Prime) Designation For Efruxifermin

Published: 10/16/2020 11:40 GMT
Akero Therapeutics Inc (AKRO) - Akero Therapeutics Receives European Medicines Agency Priority Medicines (prime) Designation for Efruxifermin (efx) in Nash.
Akero Therapeutics - Designation Was Granted Based on Positive Efficacy Data Recently Reported From Phase 2a Balanced Study.
Akero Therapeutics - Plans to Initiate Phase 2b/3 Adaptive Trial of Efx in Biopsy-confirmed Nash Patients in H1 2021.